Tags

Type your tag names separated by a space and hit enter

Interaction between the protective effects of cannabidiol and palmitoylethanolamide in experimental model of multiple sclerosis in C57BL/6 mice.
Neuroscience 2015; 290:279-87N

Abstract

Cannabinoids (CBs) have recently been approved to exert broad anti-inflammatory activities in experimental models of multiple sclerosis (MS). It has been demonstrated that these compounds could also have effects on neurodegeneration, demyelination, and autoimmune processes occurring in the pathology of MS. However, the clinical use of CBs is limited by their psychoactive effects. Among cannabinoid compounds, cannabidiol (CBD) and palmitoylethanolamide (PEA) have no psychotropic activities. We induced experimental autoimmune encephalomyelitis (EAE), a model of MS, by injecting myelin oligodendrocyte glycoprotein (MOG) to C57BL/6 mice. We assessed the effects of CBD, PEA, and co-administration of CBD and PEA on neurobehavioral scores, immune cell infiltration, demyelination, axonal injury, and the expression of inflammatory cytokines by using histochemistry methods and real-time RT-PCR. Treatment with either CBD (5mg/kg) or PEA (5mg/kg) during disease onset reduced the severity of the neurobehavioral scores of EAE. This effect of CBD and PEA was accompanied by diminished inflammation, demyelination, axonal damage and inflammatory cytokine expression while concurrent administration of CBD (5mg/kg) and PEA (5mg/kg) was not as effective as treatment with either drug per se. These results suggest that, CBD and PEA, non-psychoactive CBs, attenuate neurobehavioral deficits, histological damage, and inflammatory cytokine expression in MOG-immunized animals. However, there is an antagonistic interaction between CBD and PEA in protection against MOG-induced disease.

Authors+Show Affiliations

Department of Pharmacology and Toxicology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.Department of Pharmacology and Toxicology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.Khatam-Al-Anbia Hospital, Shefa Neuroscience Research Center, Tehran, Iran.Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.Department of Pharmacology and Toxicology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.Department of Pharmacology and Toxicology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

25637488

Citation

Rahimi, A, et al. "Interaction Between the Protective Effects of Cannabidiol and Palmitoylethanolamide in Experimental Model of Multiple Sclerosis in C57BL/6 Mice." Neuroscience, vol. 290, 2015, pp. 279-87.
Rahimi A, Faizi M, Talebi F, et al. Interaction between the protective effects of cannabidiol and palmitoylethanolamide in experimental model of multiple sclerosis in C57BL/6 mice. Neuroscience. 2015;290:279-87.
Rahimi, A., Faizi, M., Talebi, F., Noorbakhsh, F., Kahrizi, F., & Naderi, N. (2015). Interaction between the protective effects of cannabidiol and palmitoylethanolamide in experimental model of multiple sclerosis in C57BL/6 mice. Neuroscience, 290, pp. 279-87. doi:10.1016/j.neuroscience.2015.01.030.
Rahimi A, et al. Interaction Between the Protective Effects of Cannabidiol and Palmitoylethanolamide in Experimental Model of Multiple Sclerosis in C57BL/6 Mice. Neuroscience. 2015 Apr 2;290:279-87. PubMed PMID: 25637488.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Interaction between the protective effects of cannabidiol and palmitoylethanolamide in experimental model of multiple sclerosis in C57BL/6 mice. AU - Rahimi,A, AU - Faizi,M, AU - Talebi,F, AU - Noorbakhsh,F, AU - Kahrizi,F, AU - Naderi,N, Y1 - 2015/01/28/ PY - 2014/05/28/received PY - 2015/01/01/revised PY - 2015/01/10/accepted PY - 2015/2/1/entrez PY - 2015/2/1/pubmed PY - 2015/12/17/medline KW - EAE KW - cannabidiol KW - cannabinoid KW - multiple sclerosis KW - palmitoylethanolamide SP - 279 EP - 87 JF - Neuroscience JO - Neuroscience VL - 290 N2 - Cannabinoids (CBs) have recently been approved to exert broad anti-inflammatory activities in experimental models of multiple sclerosis (MS). It has been demonstrated that these compounds could also have effects on neurodegeneration, demyelination, and autoimmune processes occurring in the pathology of MS. However, the clinical use of CBs is limited by their psychoactive effects. Among cannabinoid compounds, cannabidiol (CBD) and palmitoylethanolamide (PEA) have no psychotropic activities. We induced experimental autoimmune encephalomyelitis (EAE), a model of MS, by injecting myelin oligodendrocyte glycoprotein (MOG) to C57BL/6 mice. We assessed the effects of CBD, PEA, and co-administration of CBD and PEA on neurobehavioral scores, immune cell infiltration, demyelination, axonal injury, and the expression of inflammatory cytokines by using histochemistry methods and real-time RT-PCR. Treatment with either CBD (5mg/kg) or PEA (5mg/kg) during disease onset reduced the severity of the neurobehavioral scores of EAE. This effect of CBD and PEA was accompanied by diminished inflammation, demyelination, axonal damage and inflammatory cytokine expression while concurrent administration of CBD (5mg/kg) and PEA (5mg/kg) was not as effective as treatment with either drug per se. These results suggest that, CBD and PEA, non-psychoactive CBs, attenuate neurobehavioral deficits, histological damage, and inflammatory cytokine expression in MOG-immunized animals. However, there is an antagonistic interaction between CBD and PEA in protection against MOG-induced disease. SN - 1873-7544 UR - https://www.unboundmedicine.com/medline/citation/25637488/Interaction_between_the_protective_effects_of_cannabidiol_and_palmitoylethanolamide_in_experimental_model_of_multiple_sclerosis_in_C57BL/6_mice_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0306-4522(15)00085-8 DB - PRIME DP - Unbound Medicine ER -